JPRN-jRCT1042220058尚未招募未知
Randomized parallel-group study to evaluate the impact of cardiac rehabilitation exercise management on improving exercise tolerance among patients with chronic heart disease using a telemetry-based biosignal measurement device - iCARE-MATE study
Watanabe Takatomo0 个研究点目标入组 170 人开始时间: 2022年8月26日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
入选标准
- •(1) Patients with a history of chronic heart failure, acute myocardial infarction, angina pectoris, or open heart surgery who are outpatients
- •(2) Patients who are 20 years of age or older at the time of obtaining consent
- •(3) Patients who can give written consent to participate in this study
- •(4) Patients whose %peak VO2 is less than 80%
排除标准
- •(1)Patients with difficulty in performing CPX and patients for whom PeakVO2 could not be measured
- •(2)Patients with heart failure symptoms NYHA3,4
- •(3)Patients who have difficulty putting on and taking off the wearable device
- •(4)Patients with dementia and patients with serious psychiatric disorders
- •(5)Other patients who are judged to be inappropriate as subjects by the principal investigator or investigators
研究者
相似试验
进行中（未招募）
不适用
A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive Pulmonary Disease COPDin subjects with Chronic Obstructive Pulmonary Disease COPDMedDRA version: 17.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2014-000611-14-GRGlaxoSmithKline Research & Development Ltd230
已完成
4 期
A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive Pulmonary Disease COPD (study 201314)COPDchronic obstructive pulmonary disease10038716NL-OMON41117GlaxoSmithKline36
进行中（未招募）
不适用
A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive Pulmonary Disease COPDEUCTR2014-000611-14-NLGlaxoSmithKline Research & Development Ltd230
进行中（未招募）
不适用
A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive Pulmonary Disease COPDin subjects with Chronic Obstructive Pulmonary Disease COPDMedDRA version: 17.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2014-000611-14-CZGlaxoSmithKline Research & Development Ltd230
进行中（未招募）
不适用
A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive Pulmonary Disease COPDin subjects with Chronic Obstructive Pulmonary Disease COPDMedDRA version: 17.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2014-000611-14-DEGlaxoSmithKline Research & Development Ltd230